Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1

Current antifibrinolytic agents reduce blood loss by inhibiting plasmin active sites (e.g., aprotinin) or by preventing plasminogen/tissue plasminogen activator (tPA) binding to fibrin clots (e.g., ε-aminocaproic acid and tranexamic acid); however, they have adverse side effects. Here, we expressed...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Med
Main Authors: Vadivel, Kanagasabai, Zaiss, Anne K., Kumar, Yogesh, Fabian, Frank M., Ismail, Ayman E. A., Arbing, Mark A., Buchholz, Wallace G., Velander, William H., Bajaj, S. Paul
Format: Artigo
Sprog:Inglês
Udgivet: MDPI 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7698382/
https://ncbi.nlm.nih.gov/pubmed/33212896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9113684
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker